JP6216772B2 - 抗ｂａｆｆ−抗ｉｌ−１７二重特異性抗体 - Google Patents

抗ｂａｆｆ−抗ｉｌ−１７二重特異性抗体 Download PDF

Info

Publication number
JP6216772B2
JP6216772B2 JP2015507095A JP2015507095A JP6216772B2 JP 6216772 B2 JP6216772 B2 JP 6216772B2 JP 2015507095 A JP2015507095 A JP 2015507095A JP 2015507095 A JP2015507095 A JP 2015507095A JP 6216772 B2 JP6216772 B2 JP 6216772B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
bispecific antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015507095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514423A5 (enExample
JP2015514423A (ja
Inventor
アラン，バレット
ジャン ベンショプ，ロバート
ジャン ベンショプ，ロバート
ルー，ジロング
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2015514423A publication Critical patent/JP2015514423A/ja
Publication of JP2015514423A5 publication Critical patent/JP2015514423A5/ja
Application granted granted Critical
Publication of JP6216772B2 publication Critical patent/JP6216772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015507095A 2012-04-20 2013-04-16 抗ｂａｆｆ−抗ｉｌ−１７二重特異性抗体 Active JP6216772B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
US61/636,302 2012-04-20
US201361768747P 2013-02-25 2013-02-25
US61/768,747 2013-02-25
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (3)

Publication Number Publication Date
JP2015514423A JP2015514423A (ja) 2015-05-21
JP2015514423A5 JP2015514423A5 (enExample) 2016-06-02
JP6216772B2 true JP6216772B2 (ja) 2017-10-18

Family

ID=48539373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507095A Active JP6216772B2 (ja) 2012-04-20 2013-04-16 抗ｂａｆｆ−抗ｉｌ−１７二重特異性抗体

Country Status (39)

Country Link
US (2) US9359448B2 (enExample)
EP (2) EP3192809B1 (enExample)
JP (1) JP6216772B2 (enExample)
KR (1) KR101673735B1 (enExample)
CN (1) CN104220455B (enExample)
AP (1) AP2014008002A0 (enExample)
AR (1) AR090626A1 (enExample)
AU (1) AU2013249546B2 (enExample)
BR (1) BR112014025649A2 (enExample)
CA (1) CA2869148C (enExample)
CL (1) CL2014002616A1 (enExample)
CO (1) CO7160039A2 (enExample)
CR (1) CR20140466A (enExample)
CY (1) CY1118824T1 (enExample)
DK (1) DK2838920T3 (enExample)
DO (1) DOP2014000234A (enExample)
EA (1) EA029185B1 (enExample)
EC (1) ECSP14023405A (enExample)
ES (2) ES2789474T3 (enExample)
GT (1) GT201400217A (enExample)
HR (1) HRP20170468T1 (enExample)
HU (1) HUE032153T2 (enExample)
IL (1) IL234965B (enExample)
IN (1) IN2014MN01876A (enExample)
LT (1) LT2838920T (enExample)
ME (1) ME02596B (enExample)
MX (1) MX367460B (enExample)
MY (1) MY173282A (enExample)
NZ (1) NZ630865A (enExample)
PE (1) PE20142147A1 (enExample)
PH (1) PH12014502333B1 (enExample)
PL (1) PL2838920T3 (enExample)
PT (1) PT2838920T (enExample)
RS (1) RS55729B1 (enExample)
SG (1) SG11201406726PA (enExample)
SI (1) SI2838920T1 (enExample)
TW (1) TWI585103B (enExample)
WO (1) WO2013158577A1 (enExample)
ZA (1) ZA201407272B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
PE20180774A1 (es) * 2015-07-23 2018-05-07 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
WO2019136311A2 (en) * 2018-01-05 2019-07-11 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN121039167A (zh) * 2022-12-28 2025-11-28 苏州创胜医药集团有限公司 包含抗baff抗体的双特异性结合蛋白及其用途
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
AU2024386429A1 (en) 2023-11-22 2026-05-21 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
AU2023474055A1 (en) 2023-11-23 2026-06-04 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025222170A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222168A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222167A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
ES2621917T3 (es) 2017-07-05
ME02596B (me) 2017-06-20
PE20142147A1 (es) 2014-12-13
GT201400217A (es) 2015-06-02
MX2014012692A (es) 2015-01-22
KR20140135830A (ko) 2014-11-26
PT2838920T (pt) 2017-05-03
BR112014025649A2 (pt) 2017-07-04
CR20140466A (es) 2014-11-13
EA029185B1 (ru) 2018-02-28
HUE032153T2 (en) 2017-09-28
AU2013249546B2 (en) 2017-10-26
EA201491622A1 (ru) 2015-01-30
ZA201407272B (en) 2016-11-30
AP2014008002A0 (en) 2014-10-31
CO7160039A2 (es) 2015-01-15
PH12014502333A1 (en) 2014-12-22
RS55729B1 (sr) 2017-07-31
TWI585103B (zh) 2017-06-01
ES2789474T3 (es) 2020-10-26
KR101673735B1 (ko) 2016-11-07
SI2838920T1 (sl) 2017-03-31
US20130280256A1 (en) 2013-10-24
PL2838920T3 (pl) 2017-07-31
EP2838920B1 (en) 2017-02-01
AR090626A1 (es) 2014-11-26
DK2838920T3 (en) 2017-04-18
CY1118824T1 (el) 2018-01-10
MY173282A (en) 2020-01-10
US9359448B2 (en) 2016-06-07
HK1201862A1 (en) 2015-09-11
SG11201406726PA (en) 2014-11-27
CN104220455A (zh) 2014-12-17
US9708402B2 (en) 2017-07-18
HRP20170468T1 (hr) 2017-06-02
CL2014002616A1 (es) 2015-01-30
NZ630865A (en) 2016-02-26
MX367460B (es) 2019-08-22
JP2015514423A (ja) 2015-05-21
CA2869148C (en) 2017-06-20
TW201402607A (zh) 2014-01-16
WO2013158577A1 (en) 2013-10-24
LT2838920T (lt) 2017-05-25
IL234965B (en) 2018-04-30
CN104220455B (zh) 2017-04-26
ECSP14023405A (es) 2015-09-30
PH12014502333B1 (en) 2014-12-22
US20160251430A1 (en) 2016-09-01
DOP2014000234A (es) 2014-11-30
EP3192809A1 (en) 2017-07-19
CA2869148A1 (en) 2013-10-24
AU2013249546A1 (en) 2014-09-25
EP3192809B1 (en) 2020-04-15
IN2014MN01876A (enExample) 2015-07-03
EP2838920A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
CA2869148C (en) Anti-baff-anti-il-17 bispecific antibodies
JP6152433B2 (ja) 抗ｔｎｆ−抗ｉｌ−１７二重特異性抗体
TWI585105B (zh) 抗ｔｎｆ／抗ｉｌ－２３雙特異性抗體
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
TW202136299A (zh) 雙特異性抗ｃｃｌ２抗體
KR20250050855A (ko) Igf1r 항체
JP6930778B2 (ja) 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
HK1201862B (en) Anti-baff-anti-il-17 bispecific antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170925

R150 Certificate of patent or registration of utility model

Ref document number: 6216772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250